Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…
Pharmaceuticals, Biotechnology and Life Sciences
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…
PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a…
PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a…
TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical…
SUNNYVALE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the…
VOQUEZNA® (vonoprazan) product photos VOQUEZNA® (vonoprazan) 20 mg and 10 mg bottle VOQUEZNA® (vonoprazan) product photos VOQUEZNA® (vonoprazan) 10 mg…
FARMINGTON HILLS, Mich., Nov. 01, 2023 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused…
$150M transaction supporting early and clinical-stage pipeline development in OSA and related sleep disorders to find oral pharmacologic solutions for…
-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)- ZUG, Switzerland and BOSTON, Oct.…
The study did not achieve statistical significance on the primary endpoint Tonix is discontinuing development of TNX-601 ER based on…